151 related articles for article (PubMed ID: 18436722)
21. Making advances in first-line chronic lymphocytic leukemia treatment.
Wierda WG
J Clin Oncol; 2012 Sep; 30(26):3162-4. PubMed ID: 22869876
[No Abstract] [Full Text] [Related]
22. Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine.
Eichbaum M; Bischofs E; Nehls K; Schneeweiss A; Sohn C
Drugs Today (Barc); 2009 Jun; 45(6):431-44. PubMed ID: 19649333
[TBL] [Abstract][Full Text] [Related]
23. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
[No Abstract] [Full Text] [Related]
24. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
[TBL] [Abstract][Full Text] [Related]
25. Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
García-Muñoz R; García DK; Roldán-Galiacho V; Merchante-Andreu M; Campeny-Najara A; Rabasa P
Ann Hematol; 2014 Apr; 93(4):699-702. PubMed ID: 23907409
[No Abstract] [Full Text] [Related]
26. Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
Montillo M; Tedeschi A; Gaidano G; Coscia M; Petrizzi VB; Orlandi E; Cascavilla N; Ghia P; Motta M; Gallamini A; Frustaci AM; Rossi D; De Paoli L; Nichelatti M; Morra E; Massaia M
Haematologica; 2014 Sep; 99(9):e159-61. PubMed ID: 24972768
[No Abstract] [Full Text] [Related]
27. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
28. Bendamustine: a new therapeutic option for hematologic malignancies.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
[No Abstract] [Full Text] [Related]
29. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
Niederle N; Megdenberg D; Balleisen L; Heit W; Knauf W; Weiß J; Freier W; Hinke A; Ibach S; Eimermacher H
Ann Hematol; 2013 May; 92(5):653-60. PubMed ID: 23340738
[TBL] [Abstract][Full Text] [Related]
30. Ofatumumab approved for advanced CLL.
Traynor K
Am J Health Syst Pharm; 2009 Dec; 66(23):2062. PubMed ID: 19923303
[No Abstract] [Full Text] [Related]
31. The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD).
Shoji J; Lew SQ
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645657
[TBL] [Abstract][Full Text] [Related]
32. [Toxicodermia by bendamustine: development of a desensization protocol].
Sangrador Pelluz C; Luis Hidalgo MM; Martínez García M; Pérez-Serrano Lainosa MD; Soler Company E
Farm Hosp; 2013; 37(5):421-3. PubMed ID: 24128107
[No Abstract] [Full Text] [Related]
33. Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
Lalic H; Aurer I; Batinic D; Visnjic D; Smoljo T; Babic A
Oncol Rep; 2022 Jun; 47(6):. PubMed ID: 35506458
[TBL] [Abstract][Full Text] [Related]
34. Huge kidneys in a patient with chronic lymphocytic leukaemia.
Esposito P; Libetta C; Rampino T; Gregorini M; Margiotta E; Dal Canton A
Br J Haematol; 2015 Feb; 168(4):470. PubMed ID: 25384540
[No Abstract] [Full Text] [Related]
35. Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy.
Traynor K
Am J Health Syst Pharm; 2013 Dec; 70(24):2162. PubMed ID: 24296835
[No Abstract] [Full Text] [Related]
36. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Ujjani C; Cheson B
Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
[TBL] [Abstract][Full Text] [Related]
38. Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia.
Small S
Clin Adv Hematol Oncol; 2013 Dec; 11(12):809-10. PubMed ID: 25016628
[No Abstract] [Full Text] [Related]
39. Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine.
Bartel C; Obermüller N; Rummel MJ; Geiger H; Hauser IA
Clin Nephrol; 2008 Apr; 69(4):285-9. PubMed ID: 18397703
[TBL] [Abstract][Full Text] [Related]
40. Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
Köppler H; Fuss H; Hurtz HJ; Knigge O; Losem C; Reschke D; Schmitz S; Weide R; Weiß J; Hallek M;
Br J Haematol; 2012 Jul; 158(2):238-241. PubMed ID: 22571691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]